Claims:

1. Use of a~~A~~n oligopeptidic compound comprising the amino acid sequence set forth in SEQ ID NO: 1, or an amino acid sequence having at least ~~85~~ 90 % sequence identity thereto, for the manufacture of a medicament~~use in the~~ for treatment of ~~a neoplastic condition~~cancer, wherein said oligopeptidic compound has activity in inhibiting the growth and/or viability of ~~neoplastic~~ cancer cells and in said treatment ~~comprises administering~~ said oligopeptidic compound is to be administered to a subject in combination with~~and~~ a checkpoint inhibitor, said checkpoint inhibitor ~~to a subject~~being an antibody which binds PD-1 or PD-L1 and blocks the interaction between PD-1 and PD-L1.

2. The use according to claim 1, wherein said oligopeptidic compound comprises an amino acid sequence having at least 95 % sequence identity to SEQ ID NO: 1.

3. The ~~oligopeptidic compound for~~ use according to claim 1 or claim 2, wherein said oligopeptidic compound comprises or consists of the amino acid sequence set forth in SEQ ID NO: 1.

~~3~~4. The ~~oligopeptidic compound for~~ use according to any one of claims 1 ~~or 2~~to 3, wherein said oligopeptidic compound is an inverso-compound, every amino acid of which is a D-amino acid.

~~4~~5. The ~~oligopeptidic compound for~~ use according to any one of claims 1 to ~~3~~4, wherein said oligopeptidic compound is selectively cytotoxic towards cancer cells.

~~5. The oligopeptidic compound for use according to any one of claims 1 to 4, wherein said checkpoint inhibitor blocks the interaction between PD-1 and PD-L1.~~

~~6. The oligopeptidic compound for use according to claim 5, wherein said checkpoint inhibitor is an antibody which binds PD-1 or an antibody which binds PD-L1.~~

~~7. The oligopeptidic compound for use according to any one of claims 1 to 4, wherein said checkpoint inhibitor blocks the interaction between CTLA-4 and CD80 or CD86.~~

~~8. The oligopeptidic compound for use according to claim 7, wherein said checkpoint inhibitor is an antibody which binds CTLA-4.~~

6. The use according to any one of claims 1 to 5, wherein the antibody is nivolumab, pembrolizumab, atezolizumab, durvalumab, tislelizumab or avelumab.

~~9~~7. The ~~oligopeptidic compound for~~ use according to any one of claims 1 to ~~8~~6, wherein said oligopeptidic compound and said checkpoint inhibitor ~~treatment comprises~~are to be separately, simultaneously or sequentially administered ~~ing said oligopeptidic compound and said checkpoint inhibitor~~ to said subject.

~~10~~8. The ~~oligopeptidic compound for~~ use according to any one of claims 1 to ~~9~~7, wherein said subject is a mammal~~, preferably a mouse, rat, guinea pig, cat, dog, pig, horse, cow, sheep, goat, monkey or ape~~.

~~11~~9. The ~~oligopeptidic compound for~~ use according to claim ~~8~~10, wherein said subject is a human.

~~12. The oligopeptidic compound for use according to any one of claims 1 to 11, wherein said neoplastic condition is cancer.~~

~~13~~10. The ~~oligopeptidic compound for~~ use according to any one of claims 1 to ~~12~~9, wherein said cancer is cervical cancer, anal cancer, vaginal cancer, vulvar cancer, penile cancer, melanoma, lung cancer, a head and neck cancer, bladder cancer, kidney cancer, Hodgkin's lymphoma, a squamous cell carcinoma or Merkel cell carcinoma.

~~14~~11. The ~~oligopeptidic compound~~ for use according to any one of claims 1 ~~12~~ to~~or 13~~ 10, wherein said cancer is microsatellite instability-high or mismatch-repair deficient.

~~15~~12. The ~~oligopeptidic compound for~~ use according to any one of claims ~~12~~ 1 to ~~14~~11, wherein said subject is HPV-positive.

~~16~~13. Use of a checkpoint inhibitor and an oligopeptidic compound in the manufacture of a medicament for treating ~~a neoplastic condition~~cancer in a subject, wherein ~~the treatment of said neoplastic condition comprises administering said medicament and a checkpoint inhibitor to a subject, and~~ said oligopeptidic compound, checkpoint inhibitor, subject, treatment and ~~neoplastic condition~~cancer are as defined in any one of claims 1 to ~~15~~12.

~~17. A kit comprising an oligopeptidic compound as defined in claim 1 and a checkpoint inhibitor.~~

~~18. The kit of claim 17, wherein said oligopeptidic compound is as defined in any one of claims 2 to 4 and said checkpoint inhibitor is as defined in any one of claims 5 to 8.~~

~~19. A product comprising an oligopeptidic compound as defined in claim 1 and a checkpoint inhibitor for separate, simultaneous or sequential use in the treatment of a neoplastic condition in a subject.~~

~~20. The product of claim 19, wherein the oligopeptidic compound, checkpoint inhibitor, neoplastic condition, treatment and subject are as defined in any one of claims 2 to 15.~~